Search Results
Dr. Hope Rugo on Trastuzumab Biosimilar in HER2-Positive Breast Cancer
Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer
Dr. Dang on the Significance of the MYL-1401O Biosimilar in HER2-Positive Metastatic Breast cancer
Optimizing Therapy in HER2+ Disease with Dr. Hope S. Rugo
Trial of proposed trastuzumab biosimilar, MYL-1401O vs herceptin
Dr. Rugo on Ongoing Trials in HER2+ Breast Cancer
Dr. Rugo Discusses a Comparative Review of Trastuzumab Biosimilars
Dr. Rugo Discusses the Equivalency of Trastuzumab Biosimilars
Hope S. Rugo, et al.
Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer
Novel Strategies for HER2+ Metastatic Breast Cancer; Biosimilars
The use of trastuzumab and biosimilars in the treatment of breast cancer
